AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|
17.9 C
New York
Tuesday, October 20, 2026

Tag: clinical trial

newsFORsourcecompanycontentinformation1releasesmarket

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at...

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian...

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Circulate Health announces exclusive partnership with Reborne to bring its advanced therapeutic plasma exchange protocols to UK for first time

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

Circulate Health announces exclusive partnership with Reborne to bring its advanced therapeutic plasma exchange protocols to UK for first time

LONDON, June 25, 2026 /PRNewswire/ -- Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital...

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers